Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ACAD's Cash-to-Debt is ranked higher than
99% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. ACAD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ACAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.56  Med: 653.7 Max: No Debt
Current: No Debt
5.56
No Debt
Equity-to-Asset 0.87
ACAD's Equity-to-Asset is ranked higher than
82% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACAD: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
ACAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.13  Med: 0.81 Max: 0.98
Current: 0.87
-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
98% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACAD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 22.73
Beneish M-Score: -0.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -163.06
ACAD's Operating Margin % is ranked lower than
60% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. ACAD: -163.06 )
Ranked among companies with meaningful Operating Margin % only.
ACAD' s Operating Margin % Range Over the Past 10 Years
Min: -269855.74  Med: -1339.85 Max: 35.82
Current: -163.06
-269855.74
35.82
Net Margin % -161.44
ACAD's Net Margin % is ranked lower than
61% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. ACAD: -161.44 )
Ranked among companies with meaningful Net Margin % only.
ACAD' s Net Margin % Range Over the Past 10 Years
Min: -269578.69  Med: -1333.65 Max: 35.93
Current: -161.44
-269578.69
35.93
ROE % -67.71
ACAD's ROE % is ranked lower than
64% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. ACAD: -67.71 )
Ranked among companies with meaningful ROE % only.
ACAD' s ROE % Range Over the Past 10 Years
Min: -138.68  Med: -66.19 Max: 72.43
Current: -67.71
-138.68
72.43
ROA % -60.67
ACAD's ROA % is ranked lower than
69% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. ACAD: -60.67 )
Ranked among companies with meaningful ROA % only.
ACAD' s ROA % Range Over the Past 10 Years
Min: -78.95  Med: -60.65 Max: 34.38
Current: -60.67
-78.95
34.38
ROC (Joel Greenblatt) % -8540.65
ACAD's ROC (Joel Greenblatt) % is ranked lower than
86% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. ACAD: -8540.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21643.52  Med: -10254.63 Max: 2028.76
Current: -8540.65
-21643.52
2028.76
3-Year Revenue Growth Rate 906.30
ACAD's 3-Year Revenue Growth Rate is ranked higher than
100% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ACAD: 906.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -77.6  Med: -23.5 Max: 906.3
Current: 906.3
-77.6
906.3
3-Year EBITDA Growth Rate -35.20
ACAD's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ACAD: -35.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4 Max: 53
Current: -35.2
0
53
3-Year EPS without NRI Growth Rate -35.40
ACAD's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. ACAD: -35.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.7 Max: 36.6
Current: -35.4
0
36.6
GuruFocus has detected 4 Warning Signs with ACADIA Pharmaceuticals Inc ACAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACAD's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

ACAD Guru Trades in Q2 2017

Paul Tudor Jones 16,847 sh (New)
Paul Singer 1,256,795 sh (+61.67%)
Jana Partners Sold Out
George Soros Sold Out
Steven Cohen 1,406,022 sh (-27.19%)
» More
Q3 2017

ACAD Guru Trades in Q3 2017

Joel Greenblatt 38,843 sh (New)
George Soros 18,300 sh (New)
Steven Cohen 500,000 sh (unchged)
Paul Tudor Jones Sold Out
Paul Singer 1,062,327 sh (-15.47%)
Steven Cohen 725,200 sh (-48.42%)
» More
Q4 2017

ACAD Guru Trades in Q4 2017

Paul Tudor Jones 51,869 sh (New)
Steven Cohen 2,396,098 sh (+230.41%)
George Soros Sold Out
Paul Singer Sold Out
Joel Greenblatt Sold Out
» More
Q1 2018

ACAD Guru Trades in Q1 2018

Steven Cohen 4,357,426 sh (+81.86%)
Steven Cohen 400,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-12-31 Sold Out 0.02%$26.84 - $39.14 $ 17.52-45%0
Joel Greenblatt 2017-12-31 Sold Out 0.02%$26.84 - $39.14 $ 17.52-45%0
Joel Greenblatt 2017-09-30 New Buy0.02%$26.76 - $38.37 $ 17.52-46%38,843
George Soros 2017-09-30 New Buy0.02%$26.76 - $38.37 $ 17.52-46%18,300
George Soros 2017-06-30 Sold Out 0.01%$25.45 - $34.71 $ 17.52-41%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ICPT, XMCE:ALM, NAS:CORT, NAS:ARNA, SZSE:002287, NAS:GBT, SZSE:002030, NAS:ESPR, XKRX:095700, NAS:INSM, BOM:539268, LSE:GNS, SZSE:002653, NYSE:CBM, NAS:ANAB, NAS:AIMT, NAS:ENTA, NAS:AKCA, NAS:PTLA, HKSE:06826 » details
Traded in other countries:DR6.Germany,
Headquarter Location:USA
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Top Ranked Articles about ACADIA Pharmaceuticals Inc

Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping World Holdings, Inc., Finish Line, Inc., Myriad Genetics, Inc., Proteostasis Therapeutics, Inc., Under Armour, Inc. and United Community Bancor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD
ACADIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ACADIA Pharmaceuticals Inc. To Contact The Firm
Thinking about buying stock in Acadia Pharmaceuticals, Deutsche Bank, General Motors, Novartis, or Spirit Airlines?
Thinking about buying and selling stock or options in ACADIA Pharmaceuticals, Dicks Sporting Goods, Lowes, Papa John's, or Valeant Pharmaceuticals?
Research Report Identifies Umpqua, Westrock, Globus Medical, Procter & Gamble, ACADIA Pharmaceuticals, and Cree with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Report: Developing Opportunities within Procter & Gamble, ACADIA Pharmaceuticals, Cree, Umpqua, Westrock, and Globus Medical — Future Expectations, Projections Moving into 2018
Consolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma – Fundamental Analysis, Key Performance Indications
Get a report before you buy ACADIA Pharmaceuticals, Deckers Outdoor Corp, GoPro, Shopify Inc. or United Parcel Service stock.
2 Stocks Move in After-Hours Trading ImmunoGen falls, Acadia rises
On Wednesday, U.S. stock market indexes closed in the green after opening lower. The S&P 500 and the Dow Jones Industrial Average recorded highs. The S&P 500 rose 0.12% points to close at 2,537.74, the Nasdaq Composite gained 0.04% to 6,534.63 and the Dow Jones increased 0.09% to 22,661.64. Read more...

Ratios

vs
industry
vs
history
PB Ratio 7.18
ACAD's PB Ratio is ranked lower than
76% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ACAD: 7.18 )
Ranked among companies with meaningful PB Ratio only.
ACAD' s PB Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.52 Max: 16.67
Current: 7.18
0.48
16.67
PS Ratio 13.66
ACAD's PS Ratio is ranked lower than
64% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACAD: 13.66 )
Ranked among companies with meaningful PS Ratio only.
ACAD' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 51.84 Max: 39600
Current: 13.66
0.66
39600
EV-to-EBIT -7.31
ACAD's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. ACAD: -7.31 )
Ranked among companies with meaningful EV-to-EBIT only.
ACAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -73.5  Med: -7.9 Max: 6.3
Current: -7.31
-73.5
6.3
EV-to-EBITDA -7.38
ACAD's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. ACAD: -7.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -73.7  Med: -7.9 Max: 6.1
Current: -7.38
-73.7
6.1
EV-to-Revenue 11.91
ACAD's EV-to-Revenue is ranked lower than
59% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. ACAD: 11.91 )
Ranked among companies with meaningful EV-to-Revenue only.
ACAD' s EV-to-Revenue Range Over the Past 10 Years
Min: -17.6  Med: 41.55 Max: 25951.9
Current: 11.91
-17.6
25951.9
Current Ratio 7.38
ACAD's Current Ratio is ranked higher than
72% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. ACAD: 7.38 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s Current Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.72 Max: 46.41
Current: 7.38
2.27
46.41
Quick Ratio 7.26
ACAD's Quick Ratio is ranked higher than
72% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. ACAD: 7.26 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s Quick Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.72 Max: 46.41
Current: 7.26
2.27
46.41
Days Inventory 213.71
ACAD's Days Inventory is ranked lower than
72% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. ACAD: 213.71 )
Ranked among companies with meaningful Days Inventory only.
ACAD' s Days Inventory Range Over the Past 10 Years
Min: 189.46  Med: 218.62 Max: 247.78
Current: 213.71
189.46
247.78
Days Sales Outstanding 51.69
ACAD's Days Sales Outstanding is ranked higher than
62% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. ACAD: 51.69 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.68  Med: 181.7 Max: 2932.17
Current: 51.69
50.68
2932.17
Days Payable 121.95
ACAD's Days Payable is ranked higher than
90% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. ACAD: 121.95 )
Ranked among companies with meaningful Days Payable only.
ACAD' s Days Payable Range Over the Past 10 Years
Min: 121.95  Med: 408.83 Max: 464.35
Current: 121.95
121.95
464.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
ACAD's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ACAD: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153  Med: -23.7 Max: -2
Current: -7.5
-153
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.72
ACAD's Price-to-Net-Cash is ranked lower than
57% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. ACAD: 8.72 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACAD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.69  Med: 6.58 Max: 19.49
Current: 8.72
0.69
19.49
Price-to-Net-Current-Asset-Value 7.46
ACAD's Price-to-Net-Current-Asset-Value is ranked lower than
58% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. ACAD: 7.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACAD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.66  Med: 6.42 Max: 18.47
Current: 7.46
0.66
18.47
Price-to-Tangible-Book 7.30
ACAD's Price-to-Tangible-Book is ranked lower than
69% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. ACAD: 7.30 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.63  Med: 6.41 Max: 18.19
Current: 7.3
0.63
18.19
Price-to-Median-PS-Value 0.26
ACAD's Price-to-Median-PS-Value is ranked higher than
84% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. ACAD: 0.26 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.57 Max: 649.2
Current: 0.26
0.02
649.2
Earnings Yield (Greenblatt) % -13.68
ACAD's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. ACAD: -13.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4328.3  Med: -7.4 Max: 51153
Current: -13.68
-4328.3
51153

More Statistics

Revenue (TTM) (Mil) $158.48
EPS (TTM) $ -2.07
Beta3.99
Volatility50.36%
52-Week Range $14.51 - 41.20
Shares Outstanding (Mil)124.83

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 257 436 693
EBIT (Mil $) -225 -77 152
EBITDA (Mil $)
EPS ($) -1.70 -0.44 0.79
EPS without NRI ($) -1.70 -0.44 0.79
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}